Guardant Health (GH) has an "underappreciated" catalyst path as the company's colorectal cancer screening tool has a "greater commercial opportunity" than previously expected, UBS said in a note emailed Friday.
The firm said it was more constructive on genomics application companies versus genomics technology companies in 2025 and that Guardant was its top pick within the group.
UBS said that a survey of physicians indicated that blood-based colorectal cancer screening tools could amount to around 10% of market share in the next one to two years, more than twice the consensus forecasts. This could be a catalyst for Guardant's Shield colorectal cancer screening tool, alongside pricing upside and medical society guidelines, according to UBS.
UBS also struck a positive tone on Natera (NTRA) which it said should continue to ramp volumes for its cancer screening tool Signatera, as well as a "positive growth trajectory" for Veracyte (VCYT).
Price: 36.78, Change: +0.19, Percent Change: +0.52
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。